Positron emission tomography molecular imaging of dopaminergic system in drug addiction

Anatomical Record

Volumn 295, Issue 5, 2012, Pages 722-733

  Hou, Haifeng ^a,b,c   Tian, Mei ^c   Zhang, Hong ^a,b,c  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c Key Laboratory of Medical Molecular Imaging of Zhejiang Province   (China)

Author keywords

Dopamine; Dopamine receptor; Drug addiction; Heroin; Positron emission tomography

Indexed keywords

DIAMORPHINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; RADIOLIGAND;

ARTICLE; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; HEROIN DEPENDENCE; HUMAN; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEIN TRANSPORT;

ANIMALS; BEHAVIOR, ADDICTIVE; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINERGIC NEURONS; HEROIN DEPENDENCE; HUMANS; NEURAL PATHWAYS; NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, DOPAMINE; REINFORCEMENT (PSYCHOLOGY); REWARD; SIGNAL TRANSDUCTION; SUBSTANCE-RELATED DISORDERS; TIME FACTORS;

EID: 84859750143     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.22457     Document Type: Article

References (137)

1. Aalto S, Hirvonen J, Kaasinen V, Hagelberg N, Kajander J, Nagren K, Seppala T, Rinne JO, Scheinin H, Hietala J. 2009. The effects of d-amphetamine on extrastriatal dopamine D2/D3 receptors: a randomized, double-blind, placebo-controlled PET study with [11C]FLB 457 in healthy subjects. Eur J Nucl Med Mol Imaging 36: 475-483.
2. Acosta-Garcia J, Hernandez-Chan N, Paz-Bermudez F, Sierra A, Erlij D, Aceves J, Floran B. 2009. D4 and D1 dopamine receptors modulate [3H] GABA release in the substantia nigra pars reticulata of the rat. Neuropharmacology 57: 725-730.
3. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders. 4th ed. Washington DC: American Psychiatric Press.
4. Bancroft J, Vukadinovic Z. 2004. Sexual addiction, sexual compulsivity, sexual impulsivity, or what? toward a theoretical model. J Sex Res 41: 225-234.
5. Bell KM, Klein EA, Widmark CB, Najafi A, Keator D. 1996. A pet study of pet FDOPA uptake in abstaining cocaine addicts. Biol Psychiatry 39: 606.
6. Block JJ. 2008. Issues for DSM-V: internet addiction. Am J Psychiatry 165: 306-307.
7. Brauer LH, Goudie AJ, de Wit H. 1997. Dopamine ligands and the stimulus effects of amphetamine: animal models versus human laboratory data. Psychopharmacology (Berl) 130: 2-13.
8. Brodie JD, Figueroa E, Dewey SL. 2003. Treating cocaine addiction: from preclinical to clinical trial experience with gamma-vinyl GABA. Synapse 50: 261-265.
9. Brownell AL. 2010. Current development of neuroimaging using PET techniques. In: The Third International Conference on the Development of Biomedical Engineering in Vietnam. Ho Chi Minh City, Vietnam: Springer. pp 27-30.
10. Callier S, Snapyan M, Le Crom S, Prou D, Vincent JD, Vernier P. 2003. Evolution and cell biology of dopamine receptors in vertebrates. Biol Cell 95: 489-502.
11. Cami J, Farre M. 2003. Drug addiction. N Engl J Med 349: 975-986.
12. Canfield DR, Spealman RD, Kaufman MJ, Madras BK. 1990. Autoradiographic localization of cocaine binding sites by [3H]CFT ([3H]WIN 35, 428) in the monkey brain. Synapse 6: 189-195.
13. Chen Q, Liu W, Li H, Zhang H, Tian M. 2011. Molecular imaging in patients with mood disorders: a review of PET findings. Eur J Nucl Med Mol Imaging 38: 1367-1380.
14. Christman DR, Hoyte RM, Wolf AP. 1970. Organic radiopharmaceuticals labeled with isotopes of short half-life. I. 11C-1-dopamine hydrochloride. J Nucl Med 11: 474-478.
15. Contet C, Kieffer BL, Befort K. 2004. Mu opioid receptor: a gateway to drug addiction. Curr Opin Neurobiol 14: 370-378.
16. Cropley VL, Fujita M, Innis RB, Nathan PJ. 2006. Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol Psychiatry 59: 898-907.
17. Czoty PW, Gage HD, Nader SH, Reboussin BA, Bounds M, Nader MA. 2007. PET imaging of dopamine D2 receptor and transporter availability during acquisition of cocaine self-administration in rhesus monkeys. J Addict Med 1: 33-39.
18. Dackis CA, Gold MS. 1985. New concepts in cocaine addiction: the dopamine depletion hypothesis. Neurosci Biobehav Rev 9: 469-477.
19. Dagher A, Bleicher C, Aston JA, Gunn RN, Clarke PB, Cumming P. 2001. Reduced dopamine D1 receptor binding in the ventral striatum of cigarette smokers. Synapse 42: 48-53.
20. Daglish MR, Williams TM, Wilson SJ, Taylor LG, Eap CB, Augsburger M, Giroud C, Brooks DJ, Myles JS, Grasby P, Lingford-Hughes AR, Nutt DJ. 2008. Brain dopamine response in human opioid addiction. Br J Psychiatry 193: 65-72.
21. De Vries TJ, Homberg JR, Binnekade R, Raaso H, Schoffelmeer AN. 2003. Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology (Berl) 168: 164-169.
22. De Vries TJ, Shaham Y, Homberg JR, Crombag H, Schuurman K, Dieben J, Vanderschuren LJ, Schoffelmeer AN. 2001. A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 7: 1151-1154.
23. De Wit H, Wise RA. 1977. Blockade of cocaine reinforcement in rats with the dopamine receptor blocker pimozide, but not with the noradrenergic blockers phentolamine or phenoxybenzamine. Can J Psychol 31: 195-203.
24. Dewey SL, Logan J, Wolf AP, Brodie JD, Angrist B, Fowler JS, Volkow ND. 1991. Amphetamine induced decreases in (18F)-N-methylspiroperidol binding in the baboon brain using positron emission tomography (PET). Synapse 7: 324-327.
25. Dewey SL, Morgan AE, Ashby CJ, Horan B, Kushner SA, Logan J, Volkow ND, Fowler JS, Gardner EL, Brodie JD. 1998. A novel strategy for the treatment of cocaine addiction. Synapse 30: 119-129.
26. Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, Hamon M. 1996. International union of pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 48: 567-592.
27. Di Chiara G, Imperato A. 1988. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85: 5274-5278.
28. Di Ciano P, Everitt BJ. 2003. The GABA(B) receptor agonist baclofen attenuates cocaine- and heroin-seeking behavior by rats. Neuropsychopharmacology 28: 510-518.
29. Dietis N, Rowbotham DJ, Lambert DG. 2011. Opioid receptor subtypes: fact or artifact? Br J Anaesth 107: 8-18.
30. Ding YS, Fowler JS, Volkow ND, Dewey SL, Wang GJ, Logan J, Gatley SJ, Pappas N. 1997. Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and L-threo-methylphenidate in the human and baboon brain. Psychopharmacology (Berl) 131: 71-78.
31. Ding YS, Fowler JS, Volkow ND, Logan J, Gatley SJ, Sugano Y. 1995. Carbon-11-d-threo-methylphenidate binding to dopamine transporter in baboon brain. J Nucl Med 36: 2298-2305.
32. Dziedzicka-Wasylewska M. 2004. Brain dopamine receptors-research perspectives and potential sites of regulation. Pol J Pharmacol 56: 659-671.
33. Elsinga PH, Hatano K, Ishiwata K. 2006. PET tracers for imaging of the dopaminergic system. Curr Med Chem 13: 2139-2153.
34. Fadda P, Scherma M, Fresu A, Collu M, Fratta W. 2003. Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. Synapse 50: 1-6.
35. Farde L, Halldin C, Muller L, Suhara T, Karlsson P, Hall H. 1994. PET study of [11C]beta-CIT binding to monoamine transporters in the monkey and human brain. Synapse 16: 93-103.
36. Fareed A, Casarella J, Amar R, Vayalapalli S, Drexler K. 2010. Methadone maintenance dosing guideline for opioid dependence, a literature review. J Addict Dis 29: 1-14.
37. Fareed A, Vayalapalli S, Stout S, Casarella J, Drexler K, Bailey SP. 2011. Effect of methadone maintenance treatment on heroin craving, a literature review. J Addict Dis 30: 27-38.
38. Farrell M, Ward J, Mattick R, Hall W, Stimson GV, des Jarlais D, Gossop M, Strang J. 1994. Methadone maintenance treatment in opiate dependence: a review. BMJ 309: 997-1001.
39. Fattore L, Spano MS, Cossu G, Deiana S, Fratta W. 2003. Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. Eur J Neurosci 17: 1723-1726.
40. Fehr C, Yakushev I, Hohmann N, Buchholz HG, Landvogt C, Deckers H, Eberhardt A, Klager M, Smolka MN, Scheurich A, Dielentheis T, Schmidt LG, Rosch F, Bartenstein P, Grunder G, Schreckenberger M. 2008. Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. Am J Psychiatry 165: 507-514.
41. Fischman MW, Foltin RW. 1991. Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br J Addict 86: 1563-1570.
42. Franken IH, Booij J, van den Brink W. 2005. The role of dopamine in human addiction: from reward to motivated attention. Eur J Pharmacol 526: 199-206.
43. Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SH, Ravert HT, Dannals RF. 1993. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35, 428 reveals marked declines in mild Parkinson's disease. Ann Neurol 34: 423-431.
44. Garris PA, Ciolkowski EL, Pastore P, Wightman RM. 1994. Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain. J Neurosci 14: 6084-6093.
45. Gerasimov MR, Ashby CJ, Gardner EL, Mills MJ, Brodie JD, Dewey SL. 1999. Gamma-vinyl GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine. Synapse 34: 11-19.
46. Gonzalez G, Sevarino K, Sofuoglu M, Poling J, Oliveto A, Gonsai K, George TP, Kosten TR. 2003. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. Addiction 98: 1625-1632.
47. Goodman A. 2008. Neurobiology of addiction. An integrative review. Biochem Pharmacol 75: 266-322.
48. Grant JE, Potenza MN, Weinstein A, Gorelick DA. 2010. Introduction to behavioral addictions. Am J Drug Alcohol Abuse 36: 233-241.
49. Greenwald M, Johanson CE, Bueller J, Chang Y, Moody DE, Kilbourn M, Koeppe R, Zubieta JK. 2007. Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiatry 61: 101-110.
50. Grunder G, Carlsson A, Wong DF. 2003. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 60: 974-977.
51. Halldin C, Foged C, Chou YH, Karlsson P, Swahn CG, Sandell J, Sedvall G, Farde L. 1998. Carbon-11-NNC 112: a radioligand for PET examination of striatal and neocortical D1-dopamine receptors. J Nucl Med 39: 2061-2068.
52. Hammers A, Lingford-Hughes A. 2006. Opioid imaging. Neuroimaging Clin N Am 16: 529-552.
53. Heinz A, Siessmeier T, Wrase J, Buchholz HG, Grunder G, Kumakura Y, Cumming P, Schreckenberger M, Smolka MN, Rosch F, Mann K, Bartenstein P. 2005. Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: a combined [18F]DOPA and [18F]DMFP PET study in detoxified alcoholic patients. Am J Psychiatry 162: 1515-1520.
54. Hietala J, West C, Syvalahti E, Nagren K, Lehikoinen P, Sonninen P, Ruotsalainen U. 1994. Striatal D2 dopamine receptor binding characteristics in vivo in patients with alcohol dependence. Psychopharmacology (Berl) 116: 285-290.
55. Hirvonen J, Nagren K, Kajander J, Hietala J. 2001. Measurement of cortical dopamine d1 receptor binding with 11C[SCH23390]: a test-retest analysis. J Cereb Blood Flow Metab 21: 1146-1150.
56. Holden C. 2001. 'Behavioral' addictions: do they exist? Science 294: 980-982.
57. Holden C. 2010. Psychiatry. Behavioral addictions debut in proposed DSM-V. Science 327: 935.
58. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ. 2003. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361: 1677-1685.
59. Johnson SW, North RA. 1992. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12: 483-488.
60. Julian MD, Martin AB, Cuellar B, Rodriguez DFF, Navarro M, Moratalla R, Garcia-Segura LM. 2003. Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. Neuroscience 119: 309-318.
61. Kessler RM, Whetsell WO, Ansari MS, Votaw JR, de Paulis T, Clanton JA, Schmidt DE, Mason NS, Manning RG. 1993. Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I]epidepride. Brain Res 609: 237-243.
62. Kieffer BL, Evans CJ. 2002. Opioid tolerance-in search of the holy grail. Cell 108: 587-590.
63. Kling MA, Carson RE, Borg L, Zametkin A, Matochik JA, Schluger J, Herscovitch P, Rice KC, Ho A, Eckelman WC, Kreek MJ. 2000. Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther 295: 1070-1076.
64. Kohler C, Hall H, Ogren SO, Gawell L. 1985. Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol 34: 2251-2259.
65. Koob GF, Le Moal M. 1997. Drug abuse: hedonic homeostatic dysregulation. Science 278: 52-58.
66. Koob GF, Stinus L, Le Moal M, Bloom FE. 1989. Opponent process theory of motivation: neurobiological evidence from studies of opiate dependence. Neurosci Biobehav Rev 13: 135-140.
67. Kreek MJ. 2000. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci 909: 186-216.
68. Kreek MJ, LaForge KS, Butelman E. 2002. Pharmacotherapy of addictions. Nat Rev Drug Discov 1: 710-726.
69. LeDuc PA, Mittleman G. 1995. Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence. Psychopharmacology (Berl) 121: 407-427.
70. Lee D, Huang W, Lim AT. 2000. Dopamine induces a biphasic modulation of hypothalamic ANF neurons: a ligand concentration-dependent effect involving D5 and D2 receptor interaction. Mol Psychiatry 5: 39-48.
71. Lewis JW, Husbands SM. 2004. The orvinols and related opioids-high affinity ligands with diverse efficacy profiles. Curr Pharm Des 10: 717-732.
72. Linden DE, Fallgatter AJ. 2009. Neuroimaging in psychiatry: from bench to bedside. Front Hum Neurosci 3: 49.
73. Logan J, Volkow ND, Fowler JS, Wang GJ, Fischman MW, Foltin RW, Abumrad NN, Vitkun S, Gatley SJ, Pappas N, Hitzemann R, Shea CE. 1997. Concentration and occupancy of dopamine transporters in cocaine abusers with [11C]cocaine and PET. Synapse 27: 347-356.
74. Mach RH, Nader MA, Ehrenkaufer RL, Gage HD, Childers SR, Hodges LM, Hodges MM, Davies HM. 2000. Fluorine-18-labeled tropane analogs for PET imaging studies of the dopamine transporter. Synapse 37: 109-117.
75. Maddux JF, Desmond DP. 2000. Addiction or dependence? Addiction 95: 661-665.
76. Maldonado R, Saiardi A, Valverde O, Samad TA, Roques BP, Borrelli E. 1997. Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature 388: 586-589.
77. Markou A, Koob GF. 1991. Postcocaine anhedonia. An animal model of cocaine withdrawal. Neuropsychopharmacology 4: 17-26.
78. Martinez D, Slifstein M, Narendran R, Foltin RW, Broft A, Hwang DR, Perez A, Abi-Dargham A, Fischman MW, Kleber HD, Laruelle M. 2009. Dopamine D1 receptors in cocaine dependence measured with PET and the choice to self-administer cocaine. Neuropsychopharmacology 34: 1774-1782.
79. Martin-Soelch C, Chevalley AF, Kunig G, Missimer J, Magyar S, Mino A, Schultz W, Leenders KL. 2001. Changes in reward-induced brain activation in opiate addicts. Eur J Neurosci 14: 1360-1368.
80. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. 1998. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35, 428. J Neurosci 18: 8417-8422.
81. Melichar JK, Hume SP, Williams TM, Daglish MR, Taylor LG, Ahmad R, Malizia AL, Brooks DJ, Myles JS, Lingford-Hughes A, Nutt DJ. 2005. Using [11C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies. J Pharmacol Exp Ther 312: 309-315.
82. Melichar JK, Myles JS, Eap CB, Nutt DJ. 2003. Using saccadic eye movements as objective measures of tolerance in methadone dependent individuals during the hydromorphone challenge test. Addict Biol 8: 59-66.
83. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. 1998. Dopamine receptors: from structure to function. Physiol Rev 78: 189-225.
84. Morgan CJ, Curran HV. 2012. Ketamine use: a review. Addiction 107: 27-38.
85. Nader MA, Morgan D, Gage HD, Nader SH, Calhoun TL, Buchheimer N, Ehrenkaufer R, Mach RH. 2006. PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nat Neurosci 9: 1050-1056.
86. Nanni C, Fanti S, Rubello D. 2007. 18F-DOPA PET and PET/CT. J Nucl Med 48: 1577-1579.
87. Noble EP. 2000. Addiction and its reward process through polymorphisms of the D2 dopamine receptor gene: a review. Eur Psychiatry 15: 79-89.
88. O'Brien C. 2011. Addiction and dependence in DSM-V. Addiction 106: 866-867.
89. O'Brien CP, Volpicelli LA, Volpicelli JR. 1996. Naltrexone in the treatment of alcoholism: a clinical review. Alcohol 13: 35-39.
90. Papp M, Klimek V, Willner P. 1994. Parallel changes in dopamine D2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine. Psychopharmacology (Berl) 115: 441-446.
91. Pelchat ML. 2009. Food addiction in humans. J Nutr 139: 620-622.
92. Piazza PV, Rouge-Pont F, Deminiere JM, Kharoubi M, Le Moal M, Simon H. 1991. Dopaminergic activity is reduced in the prefrontal cortex and increased in the nucleus accumbens of rats predisposed to develop amphetamine self-administration. Brain Res 567: 169-174.
93. Pichler BJ, Judenhofer MS, Pfannenberg C. 2008. Multimodal imaging approaches: PET/CT and PET/MRI. Handb Exp Pharmacol: 109-132.
94. Pichler BJ, Kolb A, Nagele T, Schlemmer HP. 2010. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med 51: 333-336.
95. Rajeswaran S, Hume SP, Cremer JE, Young J, Bailey DL, Ashburner J, Luthra SK, Jones AK, Jones T. 1991. Dynamic monitoring of [11C]diprenorphine in rat brain using a prototype positron imaging device. J Neurosci Methods 40: 223-232.
96. Rinne JO, Laihinen A, Nagren K, Ruottinen H, Ruotsalainen U, Rinne UK. 1995. PET examination of the monoamine transporter with [11C]beta-CIT and [11C]beta-CFT in early Parkinson's disease. Synapse 21: 97-103.
97. Saxe R, Carey S, Kanwisher N. 2004. Understanding other minds: linking developmental psychology and functional neuroimaging. Annu Rev Psychol 55: 87-124.
98. Schultz W. 1998. Predictive reward signal of dopamine neurons. J Neurophysiol 80: 1-27.
99. Seeman P, Tallerico T. 2003. Link between dopamine D1 and D2 receptors in rat and human striatal tissues. Synapse 47: 250-254.
100. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Takei N, Mori N. 2001. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158: 1206-1214.
101. Sekine Y, Minabe Y, Ouchi Y, Takei N, Iyo M, Nakamura K, Suzuki K, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Mori N. 2003. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry 160: 1699-1701.
102. Shi J, Zhao LY, Copersino ML, Fang YX, Chen Y, Tian J, Deng Y, Shuai Y, Jin J, Lu L. 2008. PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users. Eur J Pharmacol 579: 160-166.
103. Simantov R. 1993. Chronic morphine alters dopamine transporter density in the rat brain: possible role in the mechanism of drug addiction. Neurosci Lett 163: 121-124.
104. Slifstein M, Kegeles LS, Gonzales R, Frankle WG, Xu X, Laruelle M, Abi-Dargham A. 2007. [11C]NNC 112 selectivity for dopamine D1 and serotonin 5-HT(2A) receptors: a PET study in healthy human subjects. J Cereb Blood Flow Metab 27: 1733-1741.
105. Smythies J. 2005. Section II. The dopamine system. Int Rev Neurobiol 64: 123-172.
106. Tsukada H, Nishiyama S, Kakiuchi T, Ohba H, Sato K, Harada N. 2001. Ketamine alters the availability of striatal dopamine transporter as measured by [(11)C]beta-CFT and [(11)C]beta-CIT-FE in the monkey brain. Synapse 42: 273-280.
107. Turjanski N, Lees AJ, Brooks DJ. 1999. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology 52: 932-937.
108. United Nations Office for Drug Control and Crime Prevention (UNODC). 2010. Word drug report. Vienna: UNODC.
109. Vallone D, Picetti R, Borrelli E. 2000. Structure and function of dopamine receptors. Neurosci Biobehav Rev 24: 125-132.
110. van Harten PN, van Trier JC, Horwitz EH, Matroos GE, Hoek HW. 1998. Cocaine as a risk factor for neuroleptic-induced acute dystonia. J Clin Psychiatry 59: 128-130.
111. Villemagne V, Yuan J, Wong DF, Dannals RF, Hatzidimitriou G, Mathews WB, Ravert HT, Musachio J, McCann UD, Ricaurte GA. 1998. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35, 428 positron emission tomography studies and direct in vitro determinations. J Neurosci 18: 419-427.
112. Volkow ND, Chang L, Wang GJ, Fowler JS, Ding YS, Sedler M, Logan J, Franceschi D, Gatley J, Hitzemann R, Gifford A, Wong C, Pappas N. 2001. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry 158: 2015-2021.
113. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley JS, Dewey S, Ashby C, Liebermann J, Hitzemann R, Et A. 1995. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 52: 456-463.
114. Volkow ND, Fowler JS. 2000. Addiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex. Cereb Cortex 10: 318-325.
115. Volkow ND, Fowler JS, Gatley SJ, Logan J, Wang GJ, Ding YS, Dewey S. 1996. PET evaluation of the dopamine system of the human brain. J Nucl Med 37: 1242-1256.
116. Volkow ND, Fowler JS, Wang GJ. 2003. Positron emission tomography and single-photon emission computed tomography in substance abuse research. Semin Nucl Med 33: 114-128.
117. Volkow ND, Fowler JS, Wang GJ, Baler R, Telang F. 2009. Imaging dopamine's role in drug abuse and addiction. Neuropharmacology 56 Suppl 1: 3-8.
118. Volkow ND, Fowler JS, Wang GJ, Hitzemann R, Logan J, Schlyer DJ, Dewey SL, Wolf AP. 1993. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 14: 169-177.
119. Volkow ND, Fowler JS, Wang GJ, Swanson JM. 2004. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 9: 557-569.
120. Volkow ND, Fowler JS, Wolf AP, Schlyer D, Shiue CY, Alpert R, Dewey SL, Logan J, Bendriem B, Christman D, Et A. 1990. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry 147: 719-724.
121. Volkow ND, Wang GJ, Fowler JS, Logan J, Hitzemann R, Ding YS, Pappas N, Shea C, Piscani K. 1996. Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcohol Clin Exp Res 20: 1594-1598.
122. Volkow ND, Wang GJ, Fowler JS, Logan J, Hitzemannn R, Gatley SJ, MacGregor RR, Wolf AP. 1996. Cocaine uptake is decreased in the brain of detoxified cocaine abusers. Neuropsychopharmacology 14: 159-168.
123. Volkow ND, Wang GJ, Fowler JS, Logan J, Jayne M, Franceschi D, Wong C, Gatley SJ, Gifford AN, Ding YS, Pappas N. 2002. "Nonhedonic" food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect. Synapse 44: 175-180.
124. Volkow ND, Wang GJ, Fowler JS, Telang F, Maynard L, Logan J, Gatley SJ, Pappas N, Wong C, Vaska P, Zhu W, Swanson JM. 2004. Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. Am J Psychiatry 161: 1173-1180.
125. Volkow ND, Wang GJ, Fowler JS, Thanos PP, Logan J, Gatley SJ, Gifford A, Ding YS, Wong C, Pappas N. 2002. Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replication study. Synapse 46: 79-82.
126. Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F. 2011. Quantification of Behavior Sackler Colloquium: addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci USA 108: 15037-15042.
127. Volkow ND, Wang GJ, Maynard L, Fowler JS, Jayne B, Telang F, Logan J, Ding YS, Gatley SJ, Hitzemann R, Wong C, Pappas N. 2002. Effects of alcohol detoxification on dopamine D2 receptors in alcoholics: a preliminary study. Psychiatry Res 116: 163-172.
128. Wallmichrath I, Szabo B. 2002. Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse. Neuroscience 113: 671-682.
129. Wang GJ, Volkow ND, Fowler JS, Logan J, Abumrad NN, Hitzemann RJ, Pappas NS, Pascani K. 1997. Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropsychopharmacology 16: 174-182.
130. Wewers ME, Dhatt R, Tejwani GA. 1998. Naltrexone administration affects ad libitum smoking behavior. Psychopharmacology (Berl) 140: 185-190.
131. Whistler JL, Chuang HH, Chu P, Jan LY, von Zastrow M. 1999. Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 23: 737-746.
132. Wise RA. 2009. Roles for nigrostriatal-not just mesocorticolimbic-dopamine in reward and addiction. Trends Neurosci 32: 517-524.
133. Wu JC, Bell K, Najafi A, Widmark C, Keator D, Tang C, Klein E, Bunney BG, Fallon J, Bunney WE. 1997. Decreasing striatal 6-FDOPA uptake with increasing duration of cocaine withdrawal. Neuropsychopharmacology 17: 402-409.
134. Yasuno F, Ota M, Ando K, Ando T, Maeda J, Ichimiya T, Takano A, Doronbekov TK, Fujimura Y, Nozaki S, Suhara T. 2007. Role of ventral striatal dopamine D1 receptor in cigarette craving. Biol Psychiatry 61: 1252-1259.
135. Zijlstra F, Booij J, van den Brink W, Franken IH. 2008. Striatal dopamine D2 receptor binding and dopamine release during cue-elicited craving in recently abstinent opiate-dependent males. Eur Neuropsychopharmacol 18: 262-270.
136. Zipursky RB, Meyer JH, Verhoeff NP. 2007. PET and SPECT imaging in psychiatric disorders. Can J Psychiatry 52: 146-157.
137. Zubieta J, Greenwald MK, Lombardi U, Woods JH, Kilbourn MR, Jewett DM, Koeppe RA, Schuster CR, Johanson CE. 2000. Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology 23: 326-334.